Lung Biotechnology Competitors and Similar CompaniesClear all
Lung Biotechnology's competitors and similar companies include TFF Pharmaceuticals, Savara, Cipla and Biogen.
 Lung Biotechnology Lung Biotechnology is a company using biotechnology to design therapies for pulmonary arterial hypertension and other fatal lung diseases. |  TFF Pharmaceuticals TFF Pharmaceuticals is a biopharmaceutical company focused on developing drug products based on the Thin Film Freezing (TFF) technology platform. |  Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. | ||
Founding Date | Founding Date 2006 | Founding Date 2018 | Founding Date 1995 | Founding Date 1935 | Founding Date 1978 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Silver Spring, US HQ | Locations Austin, US HQ | Locations Austin, US HQ Hørsholm, DK | Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more |
Employees | Employees N/A | Employees 1927% increase | Employees 2827% increase | Employees 27,764 | Employees 7,605 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 8.5 m | Valuation ($) 605.7 m | Valuation ($) N/A | Valuation ($) 26.7 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $733.9k (FY, 2023) | Revenue (est.) N/A | Revenue (est.) ₹277.1b (FY, 2026) | Revenue (est.) $9.9b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods ₹95.5b (FY, 2026) | Cost of goods $2.4b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit ₹195b (FY, 2026) | Gross profit $7.5b (FY, 2025) |
Net income | Net income N/A | Net income ($21.2m) (FY, 2023) | Net income ($118.8m) (FY, 2025) | Net income ₹38.7b (FY, 2026) | Net income $1.3b (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 22.3m | Total funding raised $ 116.1m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
TFF Pharmaceuticals
HQ
Austin, US
Employees
19↑ 27% increase
TFF Pharmaceuticals is a biopharmaceutical company focused on developing drug products based on the Thin Film Freezing (TFF) technology platform.
View company
Savara
HQ
Austin, US
Employees
28↑ 27% increase
Savara (also known as Savara Pharmaceuticals) is an orphan lung disease company.
View companyCipla
HQ
Mumbai, IN
Employees
27,764
Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
View companyBiogen
HQ
Cambridge, US
Employees
7,605
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases.
View company